Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains ...

Police in the United States rarely face criminal charges when civilians die after the use of force such as physical blows, ...

Investment themes to consider for 2025 include the AI revolution, data centers, power, biotech, regional banks, defense ...

The incoming Trump administration aims to plot a new course for the Centers for Medicare and Medicaid Services — and ...

As a lifelong bicyclist, I’ve logged tens of thousands of miles commuting in urban areas, pedaling to and from work, enjoying ...

With the rapidly evolving regulatory landscape, staying on top of the latest updates is crucial for companies in biopharma and medical devices.

“These findings suggest that BMI and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a ...